Bromazepam

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Bromazepam, Lexotanil; Belgium: Bromatop, Bromazepam, Bromiden, Docbromaze, Lexotan; Bulgaria: Bromazepam, Lexotan; Cyprus: Lexilium; Czech Republic: Lexaurin; Denmark: Bromam, Lexotan; Estonia: Bromazepam, Lexotanil; France: Anxyrex, Bromazepam, Lexomil, Quietiline; Germany: Bromazanil, Bromazep, Bromazepam, Gityl, Lexostad, Lexotanil, Neo Opt, Normoc; Greece: Anconevron, Bromazepam, Evagelin, Lexotanil, Libronil, Notorium, Pascalium; Hungary: Bromazepam; Ireland: Lexotan; Italy: Brixopan, Bromazepam, Compendium, Lexotan; Luxembourg: Bromazanil, Bromazepam, Bromidem, Lexotan; Lithuania: Bromazepam, Lexotanil; Netherlands: Bromazepam; Poland: Lexotan, Sedam; Portugal: Bromalex, Bromazepam, Lexotan, Ultramidol; Romania: Bromazepam, Lexotan; Slovakia: Lexaurin; Slovenia: Lekotam, Lexaurin, Lexilium; Spain: Lexatín.

North America

Canada: Bromazepam, Lectopam.

Latin America

Argentina: Atemperator, Balamol, Bromazepam, Butecam, Creosedín, Equisedín, Estomina, Fabozepam, Finatén, Gasmol, Lexotanil, Neurozepam, Nulastres, Octanyl, Sipcar, Tritopam; Brazil: Bromazepam, Bromoxon, Lexfast, Lexotan, Lezepan, Nervium, Neurilan, Relaxil, Somalium, Uni Bromazepax; Mexico: Bromazepam, Lexotán, Otedram.

Asia

Japan: Lexotan, Seniran.

Drug combinations

Chemistry

Bromazepam: C~14~H~10~BrN~3~O. Mw: 316.15. (1) 2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-; (2) 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one. CAS-1812-30-2 (1969).

Pharmacologic Category

Anxiolytics, Sedatives, and Hypnotics; Benzodiazepines. (ATC-Code: N05BA08).

Mechanism of action

Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron in the Central Nervous System (limbic system, reticular formation). Enhances the inhibitory GABA-effect on neuronal excitability by increasing cellular permeability to chloride ions, resulting in hyperpolarization (a less excitable state) and stabilization of cellular membrane.

Therapeutic use

Short-term, symptomatic treatment of anxiety.

Pregnancy and lactiation implications

Crosses the placenta and provokes fetal damage. Use is contraindicated during pregnancy or lactation (causes sedation in the infant).

Unlabeled use

Contraindications

Hypersensitivity to bromazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist). Myasthenia gravis. Narrow-angle glaucoma. Pregnancy. Severe hepatic/respiratory disease. Sleep apnea.

Warnings and precautions

Benzodiazepines have been associated with anterograde amnesia. May cause CNS depression (effects with other sedative drugs or ethanol may be potentiated). Paradoxical reactions, including hyperactive or aggressive behavior, reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients. Use caution in depression, particularly if suicidal risk may be present. Use with caution in history of drug abuse or acute alcoholism (potential for drug dependency exists). Tolerance, psychological and physical dependence may occur with prolonged use. Use with caution in renal/hepatic impairment, impaired gag reflux, respiratory disease, and in debilitated patients. Use with extreme caution in patients who are at risk of falls (benzodiazepines have been associated with falls and traumatic injury). Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose (flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart